Portal de Periódicos da CAPES

Arachidonoyl serotonin (AA-5-HT) modulates general fear-like behavior and inhibits mesolimbic dopamine release

2019; Elsevier BV; Volume: 362; Linguagem: Inglês

10.1016/j.bbr.2019.01.010

1872-7549

Timothy G. Freels, Deranda B. Lester, Melloni N. Cook,

Psychedelics and Drug Studies

Cannabinergic and vanilloidergic signaling are potential mechanisms for the treatment of anxiety symptoms because of the anxiolytic properties of cannabinoid type 1 receptor (CB1R) activation and transient potential vanilloid type 1 channel (TRPV1) inhibition. Arachidonoyl serotonin (AA-5-HT), a fatty acid amide hydrolase and TRPV1 inhibitor provides a means of modulating these systems. We examined the effects of AA-5-HT on anxiety- and fear-like behaviors in male low (C57BL/6 J; [B6]) and high (BALB/cJ; [BCJ]) anxiety mice in light/dark box (LDB), open-field (OF), and fear extinction (FE) paradigms. AA-5-HT (1 mg/kg) did not affect anxiety-related behaviors in the LDB or OF in B6 mice. However, AA-5-HT attenuated generalized fear compared to vehicle treated B6s. AA-5-HT increased rearing and locomotion in the LDB in BCJ mice but did not affect fear-related behaviors. in vivo amperometry was used to determine the effects of AA-5-HT on dopamine release in the basolateral amygdala (BLA) and nucleus accumbens (NAc). AA-5-HT inhibited dopamine release in the BLA of BCJs and the NAc of B6s. Our results indicate that context interacts with basal anxiety levels to modulate the effects of AA-5-HT on some anxiety- and fear-related behaviors. We also provide evidence of cannabinergic and dopaminergic interactions in the BLA which could affect anxiety and fear. We suggest that this dose of AA-5-HT exhibits limited utility as a treatment for anxiety symptoms because it affects only some aspects of anxiety- and fear-related behavior in a manner dependent on baseline anxiety and environmental context.